{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:37:40Z","timestamp":1790339860212,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K21185"],"award-info":[{"award-number":["16K21185"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.omto.2020.06.021","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T01:13:29Z","timestamp":1593047609000},"page":"262-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"Wataru","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyasu","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Noma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Nishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Urata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2020.06.021_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.omto.2020.06.021_bib2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2020.06.021_bib3","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.omto.2020.06.021_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","article-title":"Japanese gastric cancer treatment guidelines 2014 (ver. 4)","volume":"20","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.omto.2020.06.021_bib5","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.6004\/jnccn.2016.0137","article-title":"Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Ajani","year":"2016","journal-title":"J.\u00a0Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.omto.2020.06.021_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","article-title":"Peritoneal-plasma barrier","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"10.1016\/j.omto.2020.06.021_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/11598890-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics","volume":"51","author":"Hasovits","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.omto.2020.06.021_bib8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2020.06.021_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.06.021_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2005.12.006","article-title":"Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma","volume":"100","author":"Trimble","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omto.2020.06.021_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/mdp260","article-title":"Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis","volume":"21","author":"Ishigami","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2020.06.021_bib12","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.28204","article-title":"A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis","volume":"119","author":"Yamaguchi","year":"2013","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.omto.2020.06.021_bib13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s10120-016-0684-3","article-title":"Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings","volume":"20","author":"Ishigami","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.omto.2020.06.021_bib14","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2020.06.021_bib15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omto.2020.06.021_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1078-0432.CCR-1075-3","article-title":"Telomerase-specific replication-selective virotherapy for human cancer","volume":"10","author":"Kawashima","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.06.021_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1349-7006.2007.00665.x","article-title":"Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus","volume":"99","author":"Hashimoto","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omto.2020.06.021_bib18","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1158\/1078-0432.CCR-10-2066","article-title":"Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas","volume":"17","author":"Sasaki","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.06.021_bib19","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1158\/1078-0432.CCR-13-0742","article-title":"A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells in S\/G2\/M phases","volume":"19","author":"Yano","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.06.021_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/mt.2009.262","article-title":"A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors","volume":"18","author":"Nemunaitis","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.06.021_bib21","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nm1404","article-title":"In\u00a0vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus","volume":"12","author":"Kishimoto","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2020.06.021_bib22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/gutjnl-2014-306957","article-title":"Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non-invasive companion diagnostics","volume":"64","author":"Shigeyasu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.omto.2020.06.021_bib23","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1111\/cas.13760","article-title":"Integrated fluorescent cytology with nano-biologics in peritoneally disseminated gastric cancer","volume":"109","author":"Watanabe","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omto.2020.06.021_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s13046-018-0981-2","article-title":"The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer","volume":"37","author":"Kuwada","year":"2018","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.06.021_bib25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/11320","article-title":"Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses","volume":"5","author":"Ikeda","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2020.06.021_bib26","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.2174\/138920112800958887","article-title":"Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer","volume":"13","author":"Fujiwara","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.omto.2020.06.021_bib27","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ijc.21846","article-title":"Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy","volume":"119","author":"Fujiwara","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omto.2020.06.021_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/cgt.2009.44","article-title":"Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination","volume":"17","author":"Takakura","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2020.06.021_bib29","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1158\/1535-7163.MCT-08-0901","article-title":"Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omto.2020.06.021_bib30","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/44188","article-title":"14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage","volume":"401","author":"Chan","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.omto.2020.06.021_bib31","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/SLA.0b013e3181deb69d","article-title":"In\u00a0vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy","volume":"251","author":"Kojima","year":"2010","journal-title":"Ann. Surg."},{"key":"10.1016\/j.omto.2020.06.021_bib32","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.1073\/pnas.0906388106","article-title":"In\u00a0vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation","volume":"106","author":"Kishimoto","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2020.06.021_bib33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3892\/or_00000720","article-title":"Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma","volume":"23","author":"Kondo","year":"2010","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.omto.2020.06.021_bib34","doi-asserted-by":"crossref","first-page":"28953","DOI":"10.1038\/srep28953","article-title":"Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas","volume":"6","author":"Osaki","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omto.2020.06.021_bib35","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.1999.17.3.1061","article-title":"Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death","volume":"17","author":"Dumontet","year":"1999","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2020.06.021_bib36","doi-asserted-by":"crossref","first-page":"9552","DOI":"10.1073\/pnas.90.20.9552","article-title":"Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations","volume":"90","author":"Jordan","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2020.06.021_bib37","first-page":"835","article-title":"Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer","volume":"4","author":"Nielsen","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2020.06.021_bib38","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/sj.cgt.7700984","article-title":"Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-small-cell lung cancer cells","volume":"13","author":"AbouEl Hassan","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2020.06.021_bib39","first-page":"517","article-title":"Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel","volume":"61","author":"Yu","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.06.021_bib40","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1083\/jcb.144.4.657","article-title":"Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus","volume":"144","author":"Suomalainen","year":"1999","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.omto.2020.06.021_bib41","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrm3115","article-title":"Mitotic catastrophe: a mechanism for avoiding genomic instability","volume":"12","author":"Vitale","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omto.2020.06.021_bib42","doi-asserted-by":"crossref","first-page":"14571","DOI":"10.1038\/s41598-017-14901-z","article-title":"Involvement of autophagy in the outcome of mitotic catastrophe","volume":"7","author":"Sorokina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omto.2020.06.021_bib43","doi-asserted-by":"crossref","first-page":"146282","DOI":"10.1155\/2015\/146282","article-title":"Targeting the Mitotic Catastrophe Signaling Pathway in Cancer","volume":"2015","author":"Mc Gee","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.omto.2020.06.021_bib44","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Galanis","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.06.021_bib45","first-page":"1562","article-title":"Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3\u00a0weeks in patients with recurrent\/refractory epithelial ovarian cancer","volume":"20","author":"Vasey","year":"2002","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2020.06.021_bib46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","article-title":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer","volume":"75","author":"Galanis","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2020.06.021_bib47","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3892\/ijo.2013.1801","article-title":"Low-dose paclitaxel modulates tumour fibrosis in gastric cancer","volume":"42","author":"Tsukada","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omto.2020.06.021_bib48","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ymthe.2020.01.003","article-title":"Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody","volume":"28","author":"Kanaya","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.06.021_bib49","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1172\/JCI38609","article-title":"A simple biological imaging system for detecting viable human circulating tumor cells","volume":"119","author":"Kojima","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2020.06.021_bib50","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770520301042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770520301042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T21:35:54Z","timestamp":1734125754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770520301042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":50,"alternative-id":["S2372770520301042"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2020.06.021","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2020.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}]}}